Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? [Yahoo! Finance]
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)
Company Research
Source: Yahoo! Finance
Limited (NYSE:TAK) reported Q3 FY2025 results on January 29, 2026, with revenue down 3.3% year-over-year at constant exchange rates due to VYVANSE's loss of exclusivity. Growth and launch products rose 6.7% at CER and now account for 52% of revenue, helping offset declines. Key drivers included Entyvio (+7.4%), Livtencity (+43.6%), and Qdenga (+22.1%), underscoring how new products are cushioning the impact of VYVANSE's 45.7% drop. Financially, Takeda posted Q3 YTD revenue of ¥3,411.2 billion, core operating profit down 3.4% to ¥971.6 billion, and reported operating profit up 1.2% to ¥422.4 billion. Cash flow remained strong, with operating cash flow up 15.8% to ¥966.9 billion and adjusted free cash flow up 10.1% to ¥625.9 billion. Looking ahead, the company is preparing to launch three transformative medicines—Oveporexton, Rusfertide, and Zasocitinib—between late 2026 and early 2027, while accelerating late-stage programs in gastrointestinal, neuroscience, and oncology to drive lon
Show less
Read more
Impact Snapshot
Event Time:
TAK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TAK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TAK alerts
High impacting Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) news events
Weekly update
A roundup of the hottest topics
TAK
News
- Is Takeda's Upgraded FY2025 Outlook And New PID Therapy Altering The Investment Case For Takeda (TSE:4502)? [Yahoo! Finance]Yahoo! Finance
- Takeda Pharmaceutical (TSE:4502) Valuation Check After Recent Share Price Momentum And Mixed Fair Value Signals [Yahoo! Finance]Yahoo! Finance
- Takeda Pharmaceutical (NYSE:TAK) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TAK&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street MarketBeat
- Takeda Tests New Highs, But Struggles To Find Entyvio Successor [Seeking Alpha]Seeking Alpha
- Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches AheadBusiness Wire
TAK
Sec Filings
- 1/29/26 - Form 6-K
- 12/18/25 - Form 6-K
- 12/9/25 - Form 144
- TAK's page on the SEC website